Pump
Lentil Peptides (PeptiPump)
Lentil peptides are marketed for pump through ACE inhibition, but no published human trial supports them.
How it counts: Not part of the score
We show it on the label and count it as disclosed, but it never affects Dose, any sub-score or the grade. The basis below explains why.
- Clinical dose
- No established clinical dose
- Safety ceiling
- —
- Evidence
- weak
- Category
- Pump
Evidence summary
Research confidence: low
No reference dose. PeptiPump is a lentil protein hydrolysate sold as a blood-flow ingredient on the idea that its peptides block ACE, as some lab studies of lentil peptides show. No human study of it has been published; the maker's own trial, registered in 2025, tests 500, 1000 and 2000 mg a day, 5-20 times the 100 mg in pre-workouts.
Research sources
- Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance (ClinicalTrials.gov NCT06894875, Nuritas Ltd)(opens in new window)
- High-pressure improves enzymatic proteolysis and the release of peptides with angiotensin I converting enzyme inhibitory and antioxidant activities from lentil proteins (Garcia-Mora et al., Food Chem 2015)(opens in new window)
Lab (in vitro) evidence that lentil protein hydrolysates contain ACE-inhibiting peptides; not PeptiPump and not a human study.